

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 11327

Title: Recent applications of chemosensitivity tests for colorectal cancer treatment

Reviewer code: 00744476

Science editor: Yuan Qi

Date sent for review: 2014-05-16 21:37

Date reviewed: 2014-06-05 04:19

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This paper is a review article about chemosensitivity for colorectal cancer (CRC). This review article is well summarized from in vitro assay to human biomarker study. As shown below, I ask authors to describe some additional information. 1. It is somehow unclear about extreme drug response assay (EDRA). More detail description about the method of EDRA would be helpful. 2. Irinotecan: Please describe about UGT1A1*6 because this polymorphism is popular in Eastern Asian population. 3. Molecular markers of anti-EGFR: BRAF is compatible with a prognostic marker, but is still controversial for a predictive marker (Eur J Cancer. 2012 Jul;48(10):1466-75). Please discuss about those. In addition, please add EGFR ligands such as amphiregulin and epiregulin. 4. Molecular markers of anti-VEGF: As authors mentioned, predictive biomarker for anti-VEGF treatment is not still convincing including SNP. However, plasma VEGF-A and neuropilin-1 in the tumor are good candidates of predictive biomarkers. Please describe about those.